Core Viewpoint - The supervisory board of Shanghai Kasei Biotechnology Co., Ltd. held a meeting to review and approve the company's 2025 semi-annual report and related proposals, ensuring compliance with legal and regulatory requirements [1][2][3][4][5] Group 1: Supervisory Board Meeting - The meeting was convened on August 15, 2025, with all three members present, confirming the legality and validity of the resolutions made [1] - The supervisory board confirmed that the 2025 semi-annual report and its summary were prepared in accordance with relevant laws and internal regulations, ensuring the information disclosed is true, accurate, and complete [1][2] Group 2: Fund Management and Usage - The board approved the special report on the storage and usage of raised funds for the first half of 2025, confirming compliance with regulatory requirements and proper management of the funds [2][3] - The company ensured that the raised funds were stored in dedicated accounts and used for specified purposes, with no violations reported [2] Group 3: Stock Incentive Plans - The board approved the cancellation of unvested restricted stock from the 2020 incentive plan, confirming that the action complies with relevant laws and does not harm the interests of the company or its shareholders [3][4] - The board also approved an adjustment to the grant price of the 2022 restricted stock incentive plan from 56.45 yuan per share to 56.05 yuan per share, ensuring the adjustment followed legal procedures [4][5] - Additionally, the board approved the cancellation of unvested restricted stock from the 2022 incentive plan, affirming compliance with applicable regulations [5]

Core Viewpoint - The company has announced the cancellation of certain unvested restricted stock from the 2020 incentive plan due to unmet performance criteria, which will not significantly impact its financial status or operational stability [1][8]. Group 1: Announcement Details - The board of directors has approved the proposal to cancel unvested restricted stock from the 2020 incentive plan [1][6]. - The company has followed the necessary decision-making procedures and disclosed relevant information regarding the incentive plan [1][2]. - The independent directors have provided their opinions on the related proposals [2][4]. Group 2: Performance Criteria - The performance targets for the fourth vesting period and the third reserved grant period required a revenue growth rate of at least 186% and a net profit growth rate of at least 186% for full vesting [6][7]. - The company's 2024 revenue was reported at 2,957.91 million, reflecting a 97.56% increase compared to 2020, while the net profit was 483.89 million, showing a 5.62% increase [7]. Group 3: Impact of Cancellation - The cancellation of the unvested restricted stock will not have a significant impact on the company's financial condition or operational performance [8]. - The cancellation marks the conclusion of the 2020 restricted stock incentive plan [8]. Group 4: Compliance and Legal Opinions - The cancellation of the unvested restricted stock complies with relevant laws and regulations, ensuring no harm to the company or shareholders [8]. - Legal opinions confirm that the necessary authorizations and approvals for the cancellation have been obtained [8].

Core Viewpoint - The company has announced adjustments to the grant price of its 2022 restricted stock incentive plan and the cancellation of certain unvested restricted stocks, following the completion of its annual profit distribution plan [1][5][8]. Summary by Sections Decision Process and Disclosure - The company has followed the necessary decision-making procedures and disclosed relevant information regarding the 2022 restricted stock incentive plan, including independent opinions from the board of directors [1][2][3]. Adjustments and Results - The grant price for the 2022 restricted stock incentive plan has been adjusted from 56.45 yuan per share to 56.05 yuan per share due to the implementation of a cash dividend distribution of 4.00 yuan per 10 shares [5][6][8]. - The adjustment is in accordance with the regulations outlined in the "Management Measures for Equity Incentives of Listed Companies" and the 2022 incentive plan [5][8]. Cancellation of Restricted Stocks - A total of 69.881 million shares of unvested restricted stocks will be canceled due to the company not meeting the performance conditions required for vesting [7][8]. - The performance conditions included a minimum revenue growth rate of 186% for the first vesting period and 107% for the second vesting period, which were not achieved [6][7]. Impact on the Company - The adjustments to the grant price and the cancellation of unvested restricted stocks are not expected to have a significant impact on the company's financial status or operational stability [8]. Supervisory Board Opinion - The supervisory board has agreed that the adjustments to the grant price and the cancellation of unvested stocks comply with relevant laws and regulations, and do not harm the interests of the company or its shareholders [8][9].

Core Viewpoint - The legal opinion issued by Shanghai Jintiancheng Law Firm confirms that the cancellation of certain unvested restricted stock awards under the 2020 incentive plan of Shanghai Kaisa Biotechnology Co., Ltd. has obtained the necessary authorizations and approvals, complying with relevant regulations [1][7][8]. Group 1: Authorization and Approval - The legal opinion is based on the compliance with the Securities Law, Company Law, and relevant regulations regarding the incentive plan [1][2]. - The company has held multiple meetings to review and approve the necessary resolutions related to the incentive plan and the cancellation of unvested stocks [3][4][5][6]. Group 2: Cancellation of Restricted Stocks - The company is required to cancel 97,650 shares of the first grant's fourth vesting period and 38,780 shares of the reserved grant's third vesting period due to unmet performance conditions [8]. - The total number of restricted stocks to be canceled amounts to 136,430 shares, which does not require further shareholder approval as per the board's authorization [8][7]. Group 3: Performance Conditions - The performance targets for the fourth vesting period and the third reserved grant period were not met, with required revenue growth rates of 186% and 107% respectively [8]. - The company's 2024 revenue was reported at 2,957.91 million yuan, a 97.56% increase from 2020, while the net profit was 483.89 million yuan, a 5.62% increase from 2020, indicating that the performance conditions were not satisfied [8].

Core Viewpoint - The legal opinion letter from Shanghai Jintiancheng Law Firm confirms that the adjustments to the 2022 restricted stock incentive plan and the cancellation of certain unvested restricted stocks have obtained the necessary authorizations and approvals, complying with relevant regulations [1][10]. Group 1: Authorization and Approval - The company has received necessary authorizations for the 2022 restricted stock incentive plan through various resolutions, including those from the independent directors and the supervisory board [3][5]. - The supervisory board has verified and issued opinions on the relevant matters of the 2022 incentive plan [4][5]. Group 2: Adjustment Details - The adjustment to the grant price of the restricted stock was necessitated by a cash dividend distribution of 4.00 yuan per 10 shares, which has been implemented [6][7]. - The adjusted grant price for the restricted stock is calculated to be 56.05 yuan per share after accounting for the dividend [7][8]. Group 3: Cancellation of Restricted Stocks - The company must cancel 69.881 million shares of unvested restricted stocks due to not meeting the performance conditions set for the third vesting period and the second vesting period of the reserved grants [8][9]. - The performance conditions required a revenue growth rate of at least 186% and a net profit growth rate of at least 186% for the first grant, and 107% for the reserved grant, which were not met [8][9].

上海凯赛生物技术股份有限公司 2025 年度提质增效重回报专项行动方案 半年度评估报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为践行"以投资者为本"的上市公司发展理念，维护上海凯赛生物技术股份 有限公司（以下简称"公司"）全体股东利益，实履行社会责任，公司于 2025 年 4 月 22 日发布了《2025 年度提质增效重回报行动方案》（以下简称"行动方 案"）。2025 年上半年，公司根据行动方案积极落实相关举措并认真评估实施效 果，公司于 2025 年 8 月 15 日召开了第二届董事会第三十四次会议审议通过了《关 于公司 2025 年度提质增效重回报专项行动方案的半年度评估报告》，现将行动方 案半年度实施情况报告如下： 一、聚焦主营业务，提升经营质量 报告期内，公司始终坚持以年初确立的发展战略，通过持续优化管理机制、 强化研发创新力度、完善生产流程体系，实现了经营效能的全面提升。在市场拓 展方面，公司保持稳健推进态势，携手下游客户积极开拓市场应用领域。得益于 全体员工的辛勤付出与不懈努力，公司在提质增效方面取 ...

上海凯赛生物技术股份有限公司 2025 年半年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 （1）2019 年公司首次公开发行股票募集资金情况 经中国证券监督管理委员会证监许可〔2020〕1439号文核准，并经上海证券 交易所同意，本公司由主承销商中信证券股份有限公司采用询价方式，向社会公 众公开发行人民币普通股（A股）股票41,668,198股，发行价每股人民币133.45 元，共计募集资金5,560,621,023.10元，坐扣承销和保荐费用278,031,051.16 元(其中，不含税承销费为人民币262,293,444.49元，该部分属于发行费用，税 款为人民币15,737,606.67元，该部分不属于发行费用)后的募集资金为 5,282,589,971.94元，已由主承销商中信证券股份有限公司于2020年8月7日汇入 本公司募集资金监管账户。另减除上网发行费、招股说明书印刷费、申报会计师 费、律师费、评估费等与 ...

证券代码：688065 证券简称：凯赛生物 公告编号：2025-042 上海凯赛生物技术股份有限公司 第二届监事会第二十七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海凯赛生物技术股份有限公司（以下简称"公司"）于 2025 年 8 月 12 日向全体 监事以邮件方式发出会议通知，并于 2025 年 8 月 15 日下午 15:00 以通讯会议的方式 召开第二届监事会第二十七次会议。本次会议由监事会主席张国华主持，会议应到 3 人，实到 3 人。本次会议的召集、召开符合《中华人民共和国公司法》（以下简称 "《公司法》"）等法律、法规、规章、规范性文件和《公司章程》的有关规定，表 决形成的决议合法、有效。 二、监事会会议审议情况 （一）审议通过《关于 2025 年半年度报告全文及其摘要的议案》 监事会认为：公司 2025 年半年度报告及摘要的编制和审议程序符合法律、行政 法规、公司章程和公司内部管理制度的各项规定；年度报告编制过程中，未发现公司 参与年度报告及摘要编制和审议的人员 ...

一、董事会会议召开情况 证券代码：688065 证券简称：凯赛生物 公告编号：2025-041 上海凯赛生物技术股份有限公司 第二届董事会第三十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海凯赛生物技术股份有限公司（以下简称"公司"）2025 年 8 月 15 日在公 司会议室召开第二届董事会第三十四次会议。本次董事会会议通知已于 2025 年 8 月 12 日以电子邮件、电话方式送达全体董事、监事和高级管理人员。本次会议由 董事长 Xiucai Liu（刘修才）主持，会议以通讯会议方式举行，会议应出席董事 9 人，实际出席董事 9 人。部分公司高级管理人员列席了本次会议。 本次会议的召集、召开符合《中华人民共和国公司法》和《公司章程》等相关 法律、法规及规范性文件的规定，会议合法有效。 二、董事会会议审议情况 （一）审议通过《关于 2025 年半年度报告全文及其摘要的议案》 根据《上市公司信息披露管理办法》《上海证券交易所科创板股票上市规则》 及中国证券监督管理委员会、上海证券交易所的其他有关规定 ...

Core Viewpoint - Kasei Biotech reported a significant increase in revenue and net profit for the first half of 2025, indicating strong financial performance and growth potential in the biotech industry [2] Financial Performance - The company's revenue for the first half of 2025 was approximately 1.671 billion yuan, representing a year-on-year increase of 15.68% [2] - The net profit attributable to shareholders was around 309 million yuan, showing a year-on-year growth of 24.74% [2] - Basic earnings per share were reported at 0.47 yuan, which is an increase of 11.9% compared to the previous year [2]